Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBL-033
- Development stage
- Phase 2
- Lead developer
- LEADS BioLabs
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LBL-033 is a bispecific T-cell engager (BiTE) antibody that targets both MUC16 (mucin 16) and CD3. By binding in a 2:1 ratio to MUC16 and CD3, it enhances aggregation in MUC16-overexpressing tumor cells while reducing non-specific activation of CD3, which may improve efficacy and minimize systemic toxicity such as cytokine release syndrome. The drug is designed to specifically target and kill MUC16-positive cancer cells by promoting immune cytokine secretion and modifying the tumor microenvironment to favor anti-tumor immunity. MUC16 is highly expressed in several malignant tumors including ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cancer, endometrial cancer, pancreatic cancer, non-small cell lung cancer, and gastric cancer. LBL-033 was developed by Leads Biolabs and is currently being evaluated in phase I/II clinical trials for advanced solid tumors including ovarian cancer[1][2][5][6].
- Other names
- anti-MUC16/anti-CD3 bispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)MUC16 (Mucin-16)
Beyond the preview
Go deeper on LBL-033.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBL-033.